TenSixty Bio
formerly TenSixty BiosciencesTransforming drug development through AI and cell biology
Cambridge, United States · Founded 2021 · $7.2M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- tensixty.bio
- Total Funding
- $7.2M
- Last Round
- $7.2M Series AAug 2022
- Rounds
- 1
About
TenSixty Bio applies AI, cell models, and high-throughput assays to identify antibody targets and develop oncology therapeutics. The team brings interdisciplinary expertise spanning biology, machine learning, and technology development.
Summary
TenSixty Bio is a Life Sciences company based in Cambridge, United States, founded in 2021. It has raised $7.2M in total across 1 round, most recently a $7.2M Series A round in Aug 2022.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2022
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...